<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003096.pub2" GROUP_ID="PREG" ID="215700080415032607" MERGED_FROM="" MODIFIED="2013-12-19 10:45:01 +0000" MODIFIED_BY="Leanne Jones" REVIEW_NO="0262" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2013-12-19 10:45:01 +0000" MODIFIED_BY="Leanne Jones">
<TITLE>Hydration for treatment of preterm labour</TITLE>
<CONTACT MODIFIED="2013-12-19 10:45:01 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="16027" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Catalin M</FIRST_NAME><LAST_NAME>Stan</LAST_NAME><POSITION>Chef de Clinique</POSITION><EMAIL_1>catalin.stan@hin.ch</EMAIL_1><ADDRESS><ORGANISATION>Private Practice</ORGANISATION><ADDRESS_1>Avenue Vinet 16</ADDRESS_1><CITY>Lausanne</CITY><ZIP>1004</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 21 6485540</PHONE_1><FAX_1>+41 21 6485542</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-19 10:45:01 +0000" MODIFIED_BY="Leanne Jones"><PERSON ID="16027" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Catalin M</FIRST_NAME><LAST_NAME>Stan</LAST_NAME><POSITION>Chef de Clinique</POSITION><EMAIL_1>catalin.stan@hin.ch</EMAIL_1><ADDRESS><ORGANISATION>Private Practice</ORGANISATION><ADDRESS_1>Avenue Vinet 16</ADDRESS_1><CITY>Lausanne</CITY><ZIP>1004</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 21 6485540</PHONE_1><FAX_1>+41 21 6485542</FAX_1></ADDRESS></PERSON><PERSON ID="5699" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michel</FIRST_NAME><LAST_NAME>Boulvain</LAST_NAME><POSITION>Médecin adjoint agrégé</POSITION><EMAIL_1>michel.boulvain@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique, Unité de Développement en Obstétrique</DEPARTMENT><ORGANISATION>Maternité Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse, 32</ADDRESS_1><CITY>Genève 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 3824317</PHONE_1><FAX_1>+41 22 3824424</FAX_1><FAX_2>+41 22 3824165</FAX_2></ADDRESS></PERSON><PERSON ID="15989" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Riccardo</FIRST_NAME><LAST_NAME>Pfister</LAST_NAME><POSITION>Médecin associé</POSITION><EMAIL_1>riccardo.pfister@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Division de Neonatologie et Soins Intensifs, Departement de Pédiatrie</DEPARTMENT><ORGANISATION>Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse 32</ADDRESS_1><CITY>Geneva 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 3824350</PHONE_1><PHONE_2>+41 22 3824351</PHONE_2><FAX_1>+41 22 3824365</FAX_1></ADDRESS></PERSON><PERSON ID="15915" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pascale</FIRST_NAME><LAST_NAME>Hirsbrunner-Almagbaly</LAST_NAME><POSITION>Chef de Clinique</POSITION><EMAIL_1>pascalehirsbrunner@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Département de Gynécologie et d'Obstétrique</DEPARTMENT><ORGANISATION>Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>Boulevard de la Cluse 32</ADDRESS_1><CITY>Geneva 14</CITY><ZIP>CH-1211</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 3824398</PHONE_1><PHONE_2>+41 22 3824397</PHONE_2><FAX_1>+41 22 3824424</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-12-05 09:48:03 +0000" MODIFIED_BY="Therese Dowswell">
<UP_TO_DATE>
<DATE DAY="3" MONTH="10" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="9" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="1" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-17 11:07:29 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-12-17 11:07:29 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="17" MONTH="12" YEAR="2013"/>
<DESCRIPTION>
<P>The graph labels for outcome 1.15 (time to delivery in days) were the wrong way around. We have therefore corrected them. There are no implications for the text of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-12-17 11:03:39 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-12-17 11:03:39 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="3" MONTH="10" YEAR="2013"/>
<DESCRIPTION>
<P>Review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-17 11:03:34 +0000" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="30" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-28 15:39:39 +0100" MODIFIED_BY="Sonja L Henderson">
<DATE DAY="31" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. No new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-24 12:21:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-11-04 15:36:31 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="6" YEAR="2007"/>
<DESCRIPTION>
<P>Search updated. One addtional trial report added to <LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK> and one additional trial report added to <LINK REF="STD-Pircon-1989" TYPE="STUDY">Pircon 1989</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-10-17 13:55:24 +0100" MODIFIED_BY="Sonja L Henderson">
<INTERNAL_SOURCES MODIFIED="2013-10-17 13:55:24 +0100" MODIFIED_BY="Sonja L Henderson">
<SOURCE>
<NAME>University of Geneva</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-10-17 13:38:44 +0100" MODIFIED_BY="Sonja L Henderson">
<SOURCE MODIFIED="2013-10-17 13:38:44 +0100" MODIFIED_BY="Sonja L Henderson">
<NAME>UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-18 14:22:33 +0000" MODIFIED_BY="Sonja L  Henderson">
<SUMMARY MODIFIED="2009-07-17 11:03:40 +0100" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2008-04-24 16:02:26 +0100" MODIFIED_BY="[Empty name]">Hydration for treatment of preterm labour</TITLE>
<SUMMARY_BODY MODIFIED="2009-07-17 11:03:40 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Unless they are dehydrated, there seems to be no benefit from additional intravenous fluids for women in preterm labour.</P>
<P>Preterm birth (before 37 weeks) can cause health problems and be life-threatening for babies. As women in preterm labour often have lower amounts of fluid in their circulation, using an intravenous drip to increase the woman's blood volume is sometimes tried (hydration). It has been hoped that the extra fluid might somehow slow down contractions. However, from the limited information available (two studies involving 228 women), the review found that there is no evidence of a benefit in the use of hydration to help prevent preterm labour, although it may be helpful for women who are dehydrated.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-10-15 16:23:41 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Hydration has been proposed as a treatment for women with preterm labour. Theoretically, hydration may reduce uterine contractility by increasing uterine blood flow and by decreasing pituitary secretion of antidiuretic hormone and oxytocin.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of intravenous or oral hydration to avoid preterm birth and its consequences in women with preterm labour.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-10-03 10:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2013) and bibliographies of relevant papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials, including women with a viable pregnancy less than 37 completed weeks' gestation and presenting with preterm labour, comparing intravenous or oral hydration with no treatment. The intervention might or might not be associated with bed rest. Studies comparing tocolytic drugs with intravenous fluids used in the control group as a placebo were not included in this review. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-10-15 16:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the reports, to determine if the study met the inclusion criteria and to evaluate the methodological quality. Data were extracted independently by two of the review authors. The results were expressed as risk ratios (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-07-03 16:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies, including a total of 228 women with preterm labour and intact membranes, compared intravenous hydration with bed rest alone. Risk of preterm delivery, before 37 weeks (RR) 1.09; 95% confidence interval (CI) 0.71 to 1.68), before 34 weeks (RR 0.72; 95% CI 0.20 to 2.56) or before 32 weeks (RR 0.76; 95% CI 0.29 to 1.97), was similar between groups. Admission to neonatal intensive care unit occurred with similar frequency in both groups (RR 0.99; 95% CI 0.46 to 2.16). Cost of treatment was slightly higher (US$39) in the hydration group. This difference was not statistically significant and only includes hospital costs during a visit of less than 24 hours. No studies evaluated oral hydration.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-10-15 16:23:41 +0100" MODIFIED_BY="Heather Maxwell">
<P>The data are too few to support the use of hydration as a specific treatment for women presenting with preterm labour. The two small studies available do not show any advantage of hydration compared with bed rest alone. Intravenous hydration does not seem to be beneficial, even during the period of evaluation soon after admission, in women with preterm labour. Women with evidence of dehydration may, however, benefit from the intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-18 14:22:33 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-10-15 16:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>Preterm birth occurs in 9.6% to 12.2% of pregnancies (<LINK REF="REF-Beck-2010" TYPE="REFERENCE">Beck 2010</LINK>; <LINK REF="REF-Martin-2011" TYPE="REFERENCE">Martin 2011</LINK>). Prematurity is the leading cause of infant deaths and is responsible for 35% of the perinatal mortality (<LINK REF="REF-Callaghan-2006" TYPE="REFERENCE">Callaghan 2006</LINK>). An evaluation of a cohort of neonates admitted to an intensive care unit after delivery at 20 to 26 weeks showed an overall survival of 57% (<LINK REF="REF-Costeloe-2012" TYPE="REFERENCE">Costeloe 2012</LINK>). Infants born preterm often require prolonged and expensive care in specialised units (<LINK REF="REF-Russel-2007" TYPE="REFERENCE">Russel 2007</LINK>). Among infants with birthweight less than 750 g, 23% of the survivors assessed at school age will suffer from neurodevelopmental impairment and 5% from cerebral palsy (<LINK REF="REF-Wilson_x002d_Costello-2007" TYPE="REFERENCE">Wilson-Costello 2007</LINK>). Infants weighting between 1000 g and 1500 g at birth are also at risk of severe mental disability (8%) and of cerebral palsy (6%) (<LINK REF="REF-Hack-1994" TYPE="REFERENCE">Hack 1994</LINK>; <LINK REF="REF-Oskoui-2013" TYPE="REFERENCE">Oskoui 2013</LINK>).</P>
<P>Preterm birth usually follows either preterm labour, preterm prelabour rupture of membranes or a medical decision to terminate the pregnancy because of maternal or fetal disease. About one-third to one-half of preterm births are the consequence of preterm labour without preterm prelabour rupture of the membranes (<LINK REF="REF-Henderson-2012" TYPE="REFERENCE">Henderson 2012</LINK>). Identification of women who will give birth preterm among those presenting with symptoms of preterm labour is difficult. As yet, risk factors, biological markers and ultrasonography are limited predictors of preterm delivery (<LINK REF="REF-Chang-2013" TYPE="REFERENCE">Chang 2013</LINK>; <LINK REF="REF-Faron-1998" TYPE="REFERENCE">Faron 1998</LINK>; <LINK REF="REF-Goldenberg-2008" TYPE="REFERENCE">Goldenberg 2008</LINK>; <LINK REF="REF-Owen-2010" TYPE="REFERENCE">Owen 2010</LINK>). Therefore, women are often evaluated for a period of time after admission, to differentiate between true and false labour.</P>
<P>Neonatal mortality and morbidity decrease as gestational age or birthweight, or both, increases (<LINK REF="REF-Bird-2010" TYPE="REFERENCE">Bird 2010</LINK>; <LINK REF="REF-Callaghan-2006" TYPE="REFERENCE">Callaghan 2006</LINK>; <LINK REF="REF-Costeloe-2012" TYPE="REFERENCE">Costeloe 2012</LINK>; <LINK REF="REF-Moutquin-2003" TYPE="REFERENCE">Moutquin 2003</LINK>). Thus, prolongation of pregnancy would be expected to decrease neonatal mortality and improve subsequent child development by reducing the effects of prematurity. However, prolonging the pregnancy is not a guarantee that the outcome for the infant will be improved (<LINK REF="REF-Hackney-2013" TYPE="REFERENCE">Hackney 2013</LINK>). There are conditions, such as intra-amniotic infection, haemolytic disease or impaired fetal growth, for which preterm delivery may be beneficial. In these cases, prolonging the pregnancy may have adverse consequences for the health and the development of the infant.</P>
<P>Despite the development of various therapeutic interventions in recent decades, little progress has been made in reducing the incidence of preterm birth (<LINK REF="REF-Haas-2012" TYPE="REFERENCE">Haas 2012</LINK>; <LINK REF="REF-Martin-2011" TYPE="REFERENCE">Martin 2011</LINK>). Pharmacological agents currently used to inhibit uterine contractions include betamimetics, magnesium sulphate, prostaglandin inhibitors, calcium channel blockers and oxytocin receptor antagonists (<LINK REF="REF-Haas-2012" TYPE="REFERENCE">Haas 2012</LINK>; <LINK REF="REF-Mackeen-2011" TYPE="REFERENCE">Mackeen 2011</LINK>). Some authors, based on uncontrolled observations, have suggested that intravenous hydration might decrease contractions or delay the delivery in women presenting with preterm contractions (<LINK REF="REF-Bieniarz-1971" TYPE="REFERENCE">Bieniarz 1971</LINK>; <LINK REF="REF-Goodlin-1981" TYPE="REFERENCE">Goodlin 1981</LINK>). Studies on plasma volume reported that women with preterm labour had lower plasma volumes than control women with a normal pregnancy (<LINK REF="REF-Goodlin-1981" TYPE="REFERENCE">Goodlin 1981</LINK>). An uncontrolled case series showed that 48% of women admitted with preterm labour did not deliver within 10 days, and one-third delivered after 37 weeks, when treated with bed rest and plasma volume expansion (<LINK REF="REF-Valenzuela-1983" TYPE="REFERENCE">Valenzuela 1983</LINK>). The above studies suffer from the limitations of not providing a comparison with controls, and, as diagnosis of preterm labour that will end in preterm birth is difficult, these results may have been achieved without any intervention.</P>
<P>How might plasma volume expansion reduce the risk of preterm birth? A possible mechanism is that volume expansion inhibits contractions by increasing uterine blood flow, thus stabilising decidual lysosomes and decreasing prostaglandin production (<LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>). Volume expansion, through left atrial distension, decreases the secretion of antidiuretic hormone from the posterior pituitary through the Henry-Gauer reflex (<LINK REF="REF-Bieniarz-1971" TYPE="REFERENCE">Bieniarz 1971</LINK>; <LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>). The hypothesis is that oxytocin secretion will decrease simultaneously (<LINK REF="REF-Bieniarz-1971" TYPE="REFERENCE">Bieniarz 1971</LINK>); however, this mechanism has only been described in animal models (<LINK REF="REF-Gauer-1976" TYPE="REFERENCE">Gauer 1976</LINK>).</P>
<P>Preterm birth is related to significant neonatal mortality and infant morbidity. Despite important research, prediction and treatment of preterm labour has little impact in decreasing the incidence of preterm births. Hydration of women in preterm labour may decrease uterine contractions by decreasing prostaglandin production or oxytocin secretion. This procedure may have a place in the management of preterm labour.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the effectiveness of intravenous or oral hydration to avoid preterm birth and its consequences in women with preterm labour.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-18 14:22:33 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-10-15 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-10-15 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials, with or without blinding, with loss to follow-up of less than 20% of women originally randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-07-03 16:15:17 +0100" MODIFIED_BY="[Empty name]">
<P>Women with a viable pregnancy less than 37 completed weeks' gestation presenting with preterm labour, as defined by the authors. A separate analysis was performed for women included before 34 completed weeks' gestation. A subgroup comparison of women with a multiple pregnancy was planned, but insufficient data were available.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intravenous or oral hydration compared with no treatment. The intervention might or might not be associated with bed rest. We have not considered in this review studies comparing tocolytic drugs with intravenous fluids used in the control group as a placebo. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-10-15 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-10-15 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Perinatal death or severe neonatal morbidity (defined as respiratory distress syndrome, intracranial haemorrhage, necrotising enterocolitis, neonatal sepsis or seizures).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-10-15 16:24:07 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Prolongation of pregnancy more than 48 hours and seven days.</LI>
<LI>Gestational age at delivery: more than 28 weeks, 32 weeks, 34 weeks and 37 weeks.</LI>
<LI>Perinatal outcomes: low birthweight (less than 2500 g), very low birthweight (less than 1500 g), Apgar score less than seven at five minutes, perinatal death, neonatal morbidity as separate outcomes (respiratory distress syndrome, intracranial haemorrhage, necrotising enterocolitis, neonatal sepsis or seizures, patent ductus arteriosus, hypoglycaemia), admission to neonatal unit and need for mechanical ventilation.</LI>
<LI>Long-term sequelae: neurologic impairment and chronic lung disease.</LI>
<LI>Serious maternal outcomes: death, cardiac arrest, respiratory arrest, pulmonary oedema, cardiac arrhythmias.</LI>
<LI>Other maternal outcomes: hypotension, chest pain, dyspnoea, nausea, vomiting, headaches, endometritis, chorioamnionitis, hyperglycaemia, hypokalaemia, women's assessment of their treatment.</LI>
</UL>
<P>Percentage of caesarean section, instrumental delivery or other outcomes that the authors of the original trials have reported would have been included in the analysis, if available. Economic evaluations of this therapy were included as an outcome. Mean interval between randomisation and delivery and the use of tocolytic drugs are reported as additional outcome measures (not prespecified).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-10-03 10:24:32 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-10-03 10:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (30 September 2013).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of Embase;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and Embase, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords. </P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-06-24 12:25:19 +0100" MODIFIED_BY="[Empty name]">
<P>We examined bibliographies of identified studies for references to other trials.</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-18 14:22:33 +0000" MODIFIED_BY="[Empty name]">
<P>Methods used in previous versions of the review are set out in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. For this update, although no new trials were added, we re-examined the trials already included in the review and carried out assessments of risk of bias and data analysis using up-to-date methods as set out in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<STUDY_SELECTION MODIFIED="2013-08-19 09:46:04 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed eligibility for inclusion of studies identified as a result of the search strategy. We resolved any disagreement through discussion or, if required, we consulted a third person.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-23 10:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, two review authors extracted the data. We resolved discrepancies through discussion or, if needed, we consulted a third person. We entered data into Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>), and checked for accuracy.</P>
<P>If information regarding any of the above was unclear, we planned to contact authors of the original reports to request further information.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-10-15 16:24:55 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreement by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>For each included study, we have described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>For each included study, we have described the method used to conceal allocation to interventions prior to assignment, and assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>For each included study, we have described the methods used, if any, to blind study participants and staff from knowledge of which intervention a participant received. We considered studies to be at low risk of bias if they were blinded, or if we judged that the lack of blinding would be unlikely to affect results.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>For each included study, we have described the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received.</P>
<P>We assessed methods as low, high or unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>For each included study and each outcome or class of outcomes, we have described the completeness of data including attrition and exclusions from the analysis. We have stated whether attrition and exclusions were reported, and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, we planned to re-include missing data in the analyses.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomisation);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>For each included study, we have described how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; or study failed to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>For each included study, we have described any important concerns we have about other possible sources of bias, such as baseline imbalance between groups.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias and assessed each as:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We made explicit judgements about whether studies are at high risk of bias, according to the criteria given in the <I>Cochrane Handbook </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it was likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses - <I>see </I>Sensitivity analysis.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-10-15 15:53:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we present results as summary risk ratio with 95% confidence intervals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we present the mean difference with 95% confidence intervals. In updates we will use the standardised mean difference to combine trials that report the same outcome, but are measured in different ways.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-10-15 16:25:16 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We did not identify any cluster-randomised trials in this version of the review. In future updates if such trials are identified we will include them in the analyses along with individually-randomised trials. We will adjust their sample sizes using the methods described in the <I>Cochrane Handbook </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely.</P>
<P>We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>Cross-over studies were not included; this is not a suitable design for this type of intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other unit of analysis issues</HEADING>
<P>If we had identified any trials with more than two arms (multi-arm trials), we planned to include all arms relevant to the scope of the review. If such trials are identified when we update the review, where appropriate, we will combine arms (using methods described in the <I>Cochrane Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)) to create a single pair-wise comparison. If it is not appropriate to combine them, we will present results separately for each arm, sharing results for the control arm between each to avoid double counting (for dichotomous outcomes we will divide the number of events and total sample by two, for continuous outcomes we will assume the same mean and standard deviation but halve the control sample size for each comparison).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-10-15 16:25:22 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis; in this version of the review only two trials were included so we did not carry out this planned additional analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all participants randomised to each group in the analyses, and all participants are analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial is the number randomised minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-12-18 14:22:17 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity using the Tau², I² and Chi² statistics. We would have regarded heterogeneity as substantial if an I² was greater than 30% and either the Tau² greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-08-16 14:07:46 +0100" MODIFIED_BY="[Empty name]">
<P>If in future updates there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-10-15 16:25:31 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using Review Manager software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We used fixed-effect meta-analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials examined the same intervention, and the trials&#8217; populations and methods were judged to be sufficiently similar. If we had suspected clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity had been detected, we planned to use random-effects meta-analysis to produce an overall summary, provided an average treatment effect across trials was considered clinically meaningful. In this version of the review, only two studies were included; we carried out meta-analysis for very few outcomes and no important statistical heterogeneity was identified.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-12-18 14:22:33 +0000" MODIFIED_BY="[Empty name]">
<P>The following comparisons were performed: any type of hydration versus bed rest alone.</P>
<P>Subgroup analysis would have included:</P>
<UL>
<LI>oral versus intravenous hydration, and</LI>
<LI>prelabour preterm rupture of membranes versus intact membranes</LI>
</UL>
<P>However, separate data were not available. We have set out data separately for a study that included women at less than 34 weeks of gestation but did not perform any formal subgroup analysis.</P>
<P>If data for subgroups become available for future updates, we will assess subgroup differences by interaction tests available within RevMan (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). We will report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-08-16 14:20:05 +0100" MODIFIED_BY="[Empty name]">
<P>If we had included cluster-randomised trials in the review, we planned to carry out sensitivity analysis. We also planned sensitivity analysis according to trial quality; temporarily excluding trials at high risk of bias due to inadequate allocation concealment to explore whether this has any impact on the direction or size of the effect estimate. In this version of the review we did not carry out any sensitivity analysis as insufficient data were available. If more data are included in updates, we will carry out planned sensitivity analysis using our primary outcomes only.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-10-15 16:26:04 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies were included (<LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>; <LINK REF="STD-Helfgott-1994" TYPE="STUDY">Helfgott 1994</LINK>). Both trials included women with preterm contractions and cervical modifications (<I>see</I> '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). Gestational age at entry ranged from 24 to 37 weeks (<LINK REF="STD-Helfgott-1994" TYPE="STUDY">Helfgott 1994</LINK>) and from 20 to 34 weeks (<LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>). Non-reassuring fetal status, suspicion of infection, maternal disease, contraindication for tocolysis, and obvious labour were exclusion criteria. In <LINK REF="STD-Helfgott-1994" TYPE="STUDY">Helfgott 1994</LINK>, hydration and hydration+morphine were compared with bed rest. The first two groups were combined, as there is no evidence of a tocolytic effect of morphine.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>The two studies included are of generally good methodological quality.</P>
<ALLOCATION MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Both studies used computer-generated randomisation sequences and allocations were concealed in opaque sealed envelopes opened sequentially.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding of women and clinical staff was not attempted in either study. The lack of blinding of staff may have affected clinical decisions that may have had an impact on outcomes introducing a serious risk of bias.</P>
<P>Blinding of outcome assessment was not mentioned, except that in the <LINK REF="STD-Helfgott-1994" TYPE="STUDY">Helfgott 1994</LINK> trial monitor tracings of uterine contractions were reported to have been examined by blinded assessors.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Eight women were excluded from the analysis (five for pyelonephritis, one refused the allocated treatment, one had ruptured membranes and one withdrew her consent) and six women were lost to follow-up in <LINK REF="STD-Helfgott-1994" TYPE="STUDY">Helfgott 1994</LINK>. This may have caused a selection bias if loss to follow-up was associated with unfavourable outcomes. There were apparently no exclusions nor losses to follow-up in the study of <LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-10-15 16:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>Selective reporting bias was not obvious although assessments were made from published study reports.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-08-21 12:49:15 +0100" MODIFIED_BY="[Empty name]">
<P>In both studies randomised groups appeared comparable at baseline, and no obvious other bias was identified.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-10-15 16:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 228 women with preterm labour and intact membranes were included in the identified studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary Outcomes</HEADING>
<P>Neither study reported on our primary outcomes (perinatal death or serious neonatal morbidity).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>Neither study reported on pregnancy prolongation of more than 48 hours or 7 days.</P>
<P>Preterm delivery before 37 weeks was similar (risk ratio (RR) 1.09; 95% confidence interval (CI) 0.71 to 1.68) in the hydration and control groups (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). Delivery before 34 weeks (RR 0.72; 95% CI 0.20 to 2.56) or before 32 weeks (RR 0.76; 95% CI 0.29 to 1.97) were also similar between groups (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Admission to neonatal intensive care unit occurred with the same frequency in both groups (RR 0.99; 95% CI 0.46 to 2.16) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>No other prespecified perinatal or maternal morbidity outcomes were reported.</P>
<P>Cost of treatment was slightly higher (US$39) in the hydration group (<LINK REF="STD-Guinn-1997" TYPE="STUDY">Guinn 1997</LINK>). This difference was not statistically significant and only included hospital costs during a visit of less than 24 hours. The interval between randomisation and delivery (not prespecified) was similar in the two groups. Slightly less use of tocolytic drugs (not prespecified) was reported in the hydration group, but this difference was not statistically significant (RR 0.83; 95% CI 0.57 to 1.20) (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
<P>Limited data are available for the subgroup of women included before 34 weeks. Results are similar to those reported in all women (Comparison 2). No trials evaluated oral hydration therapy.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-10-15 16:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>The two included studies were of good methodological quality. Both used intravenous hydration. They reported no significant benefit of hydration, as compared with bed rest in women with preterm labour. The diagnosis of preterm labour is difficult, as shown by the fact that less than 30% of the participants delivered preterm. Also, only about 30% of women received tocolytic drugs after a period of evaluation with either bed rest alone or hydration. Allowing a period of evaluation before beginning therapeutic interventions with tocolytic drugs is probably justified. This may avoid unnecessary treatment and any associated risk of side effects. It does not seem beneficial to use intravenous hydration during this period of evaluation, except in women with evidence of dehydration. For this subgroup of women hydration should not be more efficient as treatment of preterm labour, but could avoid maternal or fetal complications related to hypovolaemia. Although the trials are of good methodological quality, the number of participants is too small to assess the impact on substantive outcomes such as perinatal morbidity and mortality. The economic evaluation only takes into account short-term direct hospital costs associated with the initial visit and the first 24 hours. There is no evidence of an economic benefit of hydration. No trials assessed women's view/satisfaction with treatment.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-10-15 16:26:12 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE>
<P>The data are too few to support the use of hydration as a specific treatment for women presenting with preterm labour. The two small studies available, conducted in women with intact membranes, do not show any advantage of hydration compared with bed rest alone. Intravenous hydration does not seem to be beneficial, even during the period of evaluation in women admitted with preterm labour. Women with evidence of dehydration may, however, benefit from the intervention.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-10-15 16:26:12 +0100" MODIFIED_BY="Heather Maxwell">
<P>Hydration does not seem to be a promising intervention in the treatment of women with suspected preterm labour. However, as the data available are scarce, the use of this intervention should limited to randomised trials with substantive outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-11-01 08:08:07 +0000" MODIFIED_BY="[Empty name]">
<P>Therese Dowswell for her help in preparing the 2013 update and Sonja Henderson for her administrative support. Therese Dowswell's and Sonja Henderson's work was financially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization. The named authors alone are responsible for the views expressed in this publication.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Pregnancy and Childbirth Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-07-03 16:20:06 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-10-17 13:36:25 +0100" MODIFIED_BY="Sonja L Henderson">
<P>The 2013 update was prepared by Catalin Stan with contributions from the other authors.</P>
<P>Catalin Stan and Michel Boulvain wrote the protocol, extracted the data and drafted the text of the first version of this review (<LINK REF="REF-Stan-2002" TYPE="REFERENCE">Stan 2002</LINK>). Pascale Hirsbrunner-Almagbaly and Riccardo Pfister contributed to the protocol and to the final text of the review. Pascale Hirsbrunner-Almagbaly did the initial search of the studies.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-23 12:02:37 +0100" MODIFIED_BY="Sonja L Henderson">
<P>We updated the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> and the <LINK TAG="DATA_COLLECTION" TYPE="SECTION">Data collection and analysis</LINK> text of the 2013 updated review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-10-15 15:09:04 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Guinn-1997" NAME="Guinn 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Guinn DA, Goepfert AR, Owen J, Brumfield C, Hauth JC. Management options in women with preterm uterine contractions: a randomized clinical trial. Am J Obstet Gynecol 1997;177:814-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guinn DA, Goepfert AR, Owen J, Brumfield C, Hauth JC</AU>
<TI>Management options in women with preterm uterine contractions: a randomized clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>177</VL>
<PG>814-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guinn DA, Goepfert AR, Owen J, Brumfield CG, Hauth JC</AU>
<TI>Management options in women with preterm uterine contractions: a randomized clinical trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>1 Pt 2</NO>
<PG>S44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Helfgott-1994" NAME="Helfgott 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Helfgott AW, Willis DC, Abuhmaad A, Raimer K, Blanco JD</AU>
<TI>Effect of hydration and/or sedation in threatened preterm labor (abstract)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>164</VL>
<PG>310</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Helfgott AW, Willis DC, Blanco JD</AU>
<TI>Is hydration and sedation beneficial in the treatment of threatened preterm labor? A preliminary report</TI>
<SO>Journal of Maternal and Fetal Medicine</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>37-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Pircon-1989" NAME="Pircon 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pircon RA, Strasser HT, Kirz DS, Towers CV</AU>
<TI>Controlled trial of hydration and bedrest vs bedrest alone in the evaluation of preterm uterine contractions</TI>
<SO>Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1-4; New Orleans, Louisiana, USA</SO>
<YR>1989</YR>
<PG>396</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pircon RA, Strassner HT, Kirz DS, Towers CV</AU>
<TI>Controlled trial of hydration and bed rest versus bed rest alone in the evaluation of preterm uterine contractions</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1989</YR>
<VL>161</VL>
<PG>775-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-10-15 15:09:04 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-10-15 15:09:04 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Beck-2010" MODIFIED="2013-09-23 10:47:00 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Beck 2010" TYPE="JOURNAL_ARTICLE">
<AU>Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al</AU>
<TI>The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>2010</YR>
<VL>88</VL>
<PG>31-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bieniarz-1971" MODIFIED="2013-08-28 15:44:17 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Bieniarz 1971" TYPE="JOURNAL_ARTICLE">
<AU>Bieniarz J, Burd L, Motew M, Scommegna A</AU>
<TI>Inhibition of uterine contractility in labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1971</YR>
<VL>111</VL>
<PG>874-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bird-2010" MODIFIED="2013-09-23 11:10:54 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Bird 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bird TM, Bronstein JM, Hall RW, Lowery CL, Nugent R, Mays GP</AU>
<TI>Late preterm infants: birth outcome and health care utilisation in the first year</TI>
<SO>Pediatrics</SO>
<YR>2010</YR>
<VL>126</VL>
<PG>e311-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callaghan-2006" MODIFIED="2013-09-23 10:50:46 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Callaghan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Callaghan WM, MacDorman MF, Rasmussen SA, Qin C, Lackritz EM</AU>
<TI>The contribution of preterm birth to infant mortality rates in the United States</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>1566-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2013" MODIFIED="2013-09-23 11:06:20 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Chang 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chang HH, Larson J, Blencowe H, Spong CY, Howson CP, Cairns-Smith S, et al</AU>
<TI>Born too soon preterm prevention analysis group. Preventing preterm births: analysis of trends and potential reductions with interventions in 39 countries with very high human development index</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<PG>223-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2013-09-23 11:42:53 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.1 [updated June 2000]</TI>
<SO>In: Review Manager (RevMan)[Computer program]. Version 4.1. Oxford, England: The Cochrane Collaboration</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Costeloe-2012" MODIFIED="2013-09-23 11:30:42 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Costeloe 2012" TYPE="JOURNAL_ARTICLE">
<AU>Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES</AU>
<TI>Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies)</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e7976</PG>
<IDENTIFIERS MODIFIED="2013-09-23 10:53:49 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-09-23 10:53:49 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1136/bmj.e7976"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Faron-1998" MODIFIED="2013-08-28 15:44:34 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Faron 1998" TYPE="JOURNAL_ARTICLE">
<AU>Faron G, Boulvain M, Irion O, Bernard PM, Fraser WD</AU>
<TI>Prediction of preterm delivery by fetal fibronectin: a meta-analysis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1998</YR>
<VL>92</VL>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gauer-1976" MODIFIED="2013-08-28 15:44:38 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Gauer 1976" TYPE="JOURNAL_ARTICLE">
<AU>Gauer OH, Henry JP</AU>
<TI>Neurohormonal control of plasma volume</TI>
<SO>International Review of Physiology</SO>
<YR>1976</YR>
<VL>9</VL>
<PG>145-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldenberg-2008" MODIFIED="2013-09-23 11:07:53 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Goldenberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Goldenberg RL, Culhane JF, Iams JD, Romero R</AU>
<TI>Epidemiology and causes of preterm birth</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>371</VL>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodlin-1981" MODIFIED="2013-08-28 15:45:03 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Goodlin 1981" TYPE="JOURNAL_ARTICLE">
<AU>Goodlin RC, Quaife MA, Dirksen JW</AU>
<TI>The significance, diagnosis, and treatment of maternal hypovolemia as associated with fetal/maternal illness</TI>
<SO>Seminars in Perinatology</SO>
<YR>1981</YR>
<VL>5</VL>
<PG>163-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haas-2012" MODIFIED="2013-09-23 11:16:39 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Haas 2012" TYPE="JOURNAL_ARTICLE">
<AU>Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ</AU>
<TI>Tocolytic therapy for preterm delivery: systematic review and network meta-analysis</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>345</VL>
<PG>e6226</PG>
<IDENTIFIERS MODIFIED="2013-09-23 11:16:39 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-09-23 11:16:39 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1136/bmj.e6226"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hack-1994" NAME="Hack 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hack M, Taylor HG, Klein N, Eiben R, Schatschneider C, Mercuri-Minich N</AU>
<TI>School-age outcomes in children with birth weights under 750 g</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<PG>753-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hackney-2013" MODIFIED="2013-09-23 11:14:12 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Hackney 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hackney DN, Olson-Chen C, Thornburg LL</AU>
<TI>What do we know about the natural outcomes of preterm labour? A systematic review and meta-analysis of women without tocolysis in preterm labour</TI>
<SO>Paediatric and Perinatal Epidemiology</SO>
<YR>2013</YR>
<VL>27</VL>
<PG>452-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2012" MODIFIED="2013-10-15 15:09:04 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Henderson 2012" TYPE="JOURNAL_ARTICLE">
<AU>Henderson JJ, McWilliam OA, Newnham JP, Pennell CE</AU>
<TI>Preterm birth aetiology 2004-2008. Maternal factors associated with three phenotypes: spontaneous preterm labour, preterm pre-labour rupture of membranes and medically indicated preterm birth</TI>
<SO>Journal of Maternal-Fetal and Neonatal Medicine</SO>
<YR>2012</YR>
<VL>25</VL>
<PG>642-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-08-16 08:46:54 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration, Available from www.cochrane-handbook.org.</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mackeen-2011" MODIFIED="2013-09-23 11:30:17 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Mackeen 2011" TYPE="COCHRANE_REVIEW">
<AU>Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, Baxter JK, Berghella V</AU>
<TI>Tocolytics for preterm premature rupture of membranes</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-09-23 11:30:17 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-09-23 11:30:17 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1002/14651858.CD007062.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Martin-2011" MODIFIED="2013-09-23 10:49:15 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Martin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Kirmeyer S, Mathews TJ, et al</AU>
<TI>Births: final data for 2009</TI>
<SO>National Vital Statistics Reports</SO>
<YR>2011</YR>
<VL>60</VL>
<PG>1-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moutquin-2003" MODIFIED="2013-09-23 11:12:25 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Moutquin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moutquin JM</AU>
<TI>Classification and heterogeneity of preterm birth</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>2003</YR>
<VL>110</VL>
<PG>30-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oskoui-2013" MODIFIED="2013-09-23 11:01:49 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Oskoui 2013" TYPE="JOURNAL_ARTICLE">
<AU>Oskoui M, Coutinho F, Dykeman J, Jetté N, Pringsheim T</AU>
<TI>An update of the prevalence of cerebral palsy: a systematic review and meta-analysis</TI>
<SO>Developmental Medicine and Child Neurology</SO>
<YR>2013</YR>
<VL>55</VL>
<PG>509-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owen-2010" MODIFIED="2013-09-23 11:09:40 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Owen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Owen J, Szychowski JM, Hankins G, Iams JD, SheffieldJS, Perez-Delboy A, et al</AU>
<TI>Vaginal Ultrasound Trial Consortium. Does midtrimester cervical length &#8805; 25mm predict preterm birth in high-risk women?</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2010</YR>
<VL>203</VL>
<PG>e1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2000" NAME="RevMan 2000" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2000</YR>
<EN>4.1 for Windows</EN>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-09-23 10:25:41 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) [Computer program]. Version 5.2.</TI>
<YR>2012</YR>
<PB>Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Russel-2007" MODIFIED="2013-09-23 10:55:29 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Russel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Russel RB, Green NS, Steiner CA, Meikle S, Howse JL, Poschman K, et al</AU>
<TI>Cost of hospitalisation for preterm and low birth weight infants in the United States</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<PG>e1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Valenzuela-1983" MODIFIED="2013-08-28 15:45:49 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Valenzuela 1983" TYPE="JOURNAL_ARTICLE">
<AU>Valenzuela G, Cline S, Hayashi RH</AU>
<TI>Follow-up of hydration and sedation in the pretherapy of premature labor</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1983</YR>
<VL>147</VL>
<PG>396-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson_x002d_Costello-2007" MODIFIED="2013-09-23 10:59:22 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Wilson-Costello 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wilson-Costello D, Friedman H, Minich N, Siner B, Taylor G, Schluchter M, et al</AU>
<TI>Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>119</VL>
<PG>37-45</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-10-15 14:59:25 +0100" MODIFIED_BY="Sonja L Henderson">
<REFERENCE ID="REF-Stan-2002" MODIFIED="2013-10-15 14:59:25 +0100" MODIFIED_BY="Sonja L Henderson" NAME="Stan 2002" TYPE="COCHRANE_REVIEW">
<AU>Stan CM, Boulvain M, Pfister R, Hirsbrunner-Almagbaly P</AU>
<TI>Hydration for treatment of preterm labour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-08-28 15:51:22 +0100" MODIFIED_BY="Sonja L Henderson">
<IDENTIFIER MODIFIED="2013-08-28 15:51:22 +0100" MODIFIED_BY="Sonja L Henderson" TYPE="DOI" VALUE="10.1002/14651858.CD003096"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-10-15 15:32:58 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-10-15 15:32:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-10-15 15:31:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guinn-1997">
<CHAR_METHODS MODIFIED="2013-08-21 12:03:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial with 3 arms and individual randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 16:21:01 +0100" MODIFIED_BY="[Empty name]">
<P>Women at 20 to 34 weeks of gestation, with a singleton pregnancy, intact membranes at risk for preterm delivery. Risk of preterm delivery was defined as: 3 or more contractions per 30 minutes, cervical dilatation of 1 cm or less, cervical effacement less than 80%. Exclusion criteria were non-reassuring fetal status, suspicion of infection and maternal disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-15 15:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>Control group: bed rest alone (56 women).<BR/>Experimental group: IV hydration with 500 mL cristalloids over 20 minutes followed by 200 mL/hour (62 women).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Interval from randomisation to delivery and to discharge, gestational age at delivery, delivery before 34 and 37 weeks, costs.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>A third group treated with terbutaline is not included in this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-10-15 15:32:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Helfgott-1994">
<CHAR_METHODS MODIFIED="2013-08-21 12:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. 3 arms with individual randomisation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-03 16:21:34 +0100" MODIFIED_BY="[Empty name]">
<P>Women at 24 to 37 weeks of gestation, with a singleton pregnancy, intact membranes at risk for preterm delivery. Risk of preterm delivery was defined as: regular painful contractions, cervical dilatation of 4 cm or less, cervical effacement less than 100%. Exclusion criteria were contraindication to tocolytics, obvious labour.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-15 15:32:58 +0100" MODIFIED_BY="[Empty name]">
<P>Control group: bed rest alone (40 women).<BR/>Experimental groups:<BR/>IV hydration only: 500 mL lactate Ringer over 30 minutes (34 women).<BR/>IV hydration and morphine: hydration as above and 8-12 mg of morphine sulphate IM (42 women).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Interval from randomisation to delivery, delivery before 32 and 37 weeks, need for additional treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Hydration only and hydration + morphine groups were combined for the purpose of this review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IM: intramuscular<BR/>IV: intravenous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-03 16:22:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-03 16:22:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pircon-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-03 16:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>Inadequate method of concealment of the allocation (alternate date). Women in the control group were treated with hydration after 2 hours if contractions persisted. 3 women were readmitted after the initial treatment and included again in the study, with a cross-over of the intervention. Report of the results is unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-08-28 15:46:23 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-08-21 12:12:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:03:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>&#8220;computer-generated randomization schedule&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:12:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>&#8220;the assignments were computer generated".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-21 12:13:12 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:04:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>&#8220;Consenting women were assigned to one of three treatment groups by opening the next sealed, opaque envelope&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:13:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>Allocations were &#8220;placed in sealed opaque envelopes, and opened at the time of entry&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-08-21 12:05:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-08-21 12:13:41 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-08-21 12:06:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>The treatment regimens were different, and clinical decisions (which may have had an impact on outcomes) were made by staff who knew which treatment women were receiving.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-08-21 12:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>Women and clinicians were not blinded, which may have affected clinical decisions about their care.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-08-21 12:15:06 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-08-21 12:10:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>Blinding of outcome assessors was not mentioned and treatment was likely to have been recorded in patient records &#8220;outcome data were abstracted from the medical record and the computerized perinatal database&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-08-21 12:15:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>It was stated that some outcome assessment was blinded, but for other outcomes it was no clear that assessors were blind to treatment group. &#8220;The monitor tracings were analysed by a blinded observer so as not to bias the information regarding uterine contractions upon entry and completion of the study&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-08-21 12:21:13 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-21 12:08:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>All participants seem to be accounted for.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-21 12:21:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>5 out of 124 women were enrolled into the study but then excluded. Another 3 subsequently left the study. Delivery information was available for 110 women, (11.3% attrition).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-28 15:46:23 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:08:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-28 15:46:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>Assessment from published study report.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-08-21 12:17:33 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guinn-1997">
<DESCRIPTION>
<P>Groups appeared similar at baseline, other bias not apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-21 12:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Helfgott-1994">
<DESCRIPTION>
<P>Groups appeared comparable at baseline. Other bias not apparent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-05 09:49:52 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-05 09:49:52 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Hydration versus no treatment/bed rest alone (all women)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-19 09:56:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-19 09:56:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Severe neonatal morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-19 09:56:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Prolongation of pregnancy more than 48 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-19 09:56:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Prolongation of pregnancy more than seven days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8511667404563417" CI_END="1.6831921430830956" CI_START="0.7063749236757335" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0903965891371432" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.22613369524953608" LOG_CI_START="-0.1509647266198419" LOG_EFFECT_SIZE="0.03758448431484707" METHOD="MH" MODIFIED="2013-08-21 12:27:45 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3562225628162097" P_Q="1.0" P_Z="0.6960266102520503" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="93" WEIGHT="100.0" Z="0.390689705193872">
<NAME>Delivery before 37 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.419626470096365" CI_START="0.720219449625099" EFFECT_SIZE="1.3200992555831266" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3837483269321498" LOG_CI_START="-0.14253515462427224" LOG_EFFECT_SIZE="0.12060658615393874" ORDER="11767" O_E="0.0" SE="0.30914152221149127" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.09556848075523797" WEIGHT="48.338730958378314"/>
<DICH_DATA CI_END="1.641253568332145" CI_START="0.4669860164796925" EFFECT_SIZE="0.8754669987546699" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.2151756833200951" LOG_CI_START="-0.33069612383780916" LOG_EFFECT_SIZE="-0.05776022025885701" ORDER="11768" O_E="0.0" SE="0.3206478016335774" STUDY_ID="STD-Helfgott-1994" TOTAL_1="73" TOTAL_2="37" VAR="0.102815012692446" WEIGHT="51.661269041621686"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5580200604280394" CI_START="0.20411207747696022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.4079039459671234" LOG_CI_START="-0.6901312969673432" LOG_EFFECT_SIZE="-0.1411136755001099" METHOD="MH" MODIFIED="2013-08-21 12:29:43 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6144241469183208" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.5037683871915474">
<NAME>Delivery before 34 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5580200604280403" CI_START="0.20411207747696017" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40790394596712354" LOG_CI_START="-0.6901312969673433" LOG_EFFECT_SIZE="-0.1411136755001099" ORDER="11766" O_E="0.0" SE="0.6449913370618188" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.41601382488479266" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9742544169009966" CI_START="0.2927771154867004" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7602739726027398" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.2954031183115837" LOG_CI_START="-0.5334628723071431" LOG_EFFECT_SIZE="-0.11902987699777964" METHOD="MH" MODIFIED="2013-08-21 12:29:43 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5734866516329729" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="37" WEIGHT="100.0" Z="0.5629239820196572">
<NAME>Delivery before 32 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.974254416900997" CI_START="0.2927771154867004" EFFECT_SIZE="0.7602739726027398" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.29540311831158383" LOG_CI_START="-0.5334628723071431" LOG_EFFECT_SIZE="-0.11902987699777964" ORDER="11765" O_E="0.0" SE="0.48687998584226533" STUDY_ID="STD-Helfgott-1994" TOTAL_1="73" TOTAL_2="37" VAR="0.23705212061376446" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.159631840635838" CI_START="0.45708642506954733" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.334379721887974" LOG_CI_START="-0.3400016765556308" LOG_EFFECT_SIZE="-0.002810977333828425" METHOD="MH" MODIFIED="2013-08-21 12:31:09 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.9869638128731713" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.01633916459848162">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.159631840635838" CI_START="0.4570864250695473" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.334379721887974" LOG_CI_START="-0.34000167655563085" LOG_EFFECT_SIZE="-0.002810977333828425" ORDER="11769" O_E="0.0" SE="0.39613497168753425" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.15692291579388357" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-15 15:27:21 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low birthweight (less than 2500 g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-15 15:26:58 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Very low birthweight (less than 1500 g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Women's assessment of their treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="104.10692657297561" CI_START="-26.10692657297561" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="39.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2008-04-24 16:09:39 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.24037619915013686" Q="0.0" RANDOM="NO" SCALE="194.5051270237203" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="1.174047054907212">
<NAME>Cost of treament (first 24 hours, in US$)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="104.10692657297561" CI_START="-26.10692657297561" EFFECT_SIZE="39.0" ESTIMABLE="YES" MEAN_1="246.0" MEAN_2="207.0" ORDER="11770" SD_1="172.0" SD_2="165.0" SE="33.218430076537494" STUDY_ID="STD-Guinn-1997" TOTAL_1="54" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.15240569538645468" CI_END="1.2005082388228436" CI_START="0.5692579281886583" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8266794014645018" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.07936514487036439" LOG_CI_START="-0.24469091214960703" LOG_EFFECT_SIZE="-0.08266288363962132" METHOD="MH" NO="14" P_CHI2="0.6962470763751978" P_Q="1.0" P_Z="0.317345628256695" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="96" WEIGHT="100.0" Z="0.9999274587353142">
<NAME>Use of tocolytic drugs (not prespecified)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7017864129960194" CI_START="0.30680864812083075" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.23090505194245328" LOG_CI_START="-0.513132402942673" LOG_EFFECT_SIZE="-0.1411136755001099" ORDER="11771" O_E="0.0" SE="0.4370512840443243" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.19101382488479263" WEIGHT="28.621458134352117"/>
<DICH_DATA CI_END="1.298601485196217" CI_START="0.5807440798820493" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="20" LOG_CI_END="0.11347589523483725" LOG_CI_START="-0.2360152087126825" LOG_EFFECT_SIZE="-0.06126965673892266" ORDER="11772" O_E="0.0" SE="0.20529280446763887" STUDY_ID="STD-Helfgott-1994" TOTAL_1="76" TOTAL_2="40" VAR="0.0421451355661882" WEIGHT="71.37854186564788"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.064287757096347" CI_END="5.87391189156679" CI_START="-7.848729905378336" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9874090069057728" ESTIMABLE="YES" I2="6.04044880415994" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2013-12-05 09:49:52 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.30223967360991677" P_Q="1.0" P_Z="0.7778995247431245" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="0.2820573647818456">
<NAME>Time to delivery (days, not prespecified)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.010467093305326" CI_START="-13.61046709330532" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="55.7" MEAN_2="60.0" ORDER="11773" SD_1="26.9" SD_2="24.7" SE="4.7503256012585435" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" WEIGHT="54.30908975042445"/>
<CONT_DATA CI_END="13.100625996917033" CI_START="-7.200625996917042" EFFECT_SIZE="2.9499999999999957" ESTIMABLE="YES" MEAN_1="49.91" MEAN_2="46.96" ORDER="11774" SD_1="25.63" SD_2="25.68" SE="5.178985979836303" STUDY_ID="STD-Helfgott-1994" TOTAL_1="73" TOTAL_2="37" WEIGHT="45.69091024957555"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-10-15 15:27:58 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Hydration versus no treatment/bed rest alone (women included before 34 weeks)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Prolongation of pregnancy more than 48 hours</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Prolongation of pregnancy more than seven days</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Delivery before 32 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5580200604280394" CI_START="0.20411207747696022" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.4079039459671234" LOG_CI_START="-0.6901312969673432" LOG_EFFECT_SIZE="-0.1411136755001099" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6144241469183208" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.5037683871915474">
<NAME>Delivery before 34 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5580200604280403" CI_START="0.20411207747696017" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.40790394596712354" LOG_CI_START="-0.6901312969673433" LOG_EFFECT_SIZE="-0.1411136755001099" ORDER="11775" O_E="0.0" SE="0.6449913370618188" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.41601382488479266" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.419626470096365" CI_START="0.720219449625099" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3200992555831266" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3837483269321498" LOG_CI_START="-0.14253515462427224" LOG_EFFECT_SIZE="0.12060658615393874" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.36901685324773537" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.8983164908044133">
<NAME>Delivery before 37 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.419626470096365" CI_START="0.720219449625099" EFFECT_SIZE="1.3200992555831266" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.3837483269321498" LOG_CI_START="-0.14253515462427224" LOG_EFFECT_SIZE="0.12060658615393874" ORDER="11776" O_E="0.0" SE="0.30914152221149127" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.09556848075523797" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-15 15:27:44 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Low birthweight (less than 2500 g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-10-15 15:27:58 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Very low birthweight (less than 1500 g)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Perinatal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Severe neonatal morbidity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.159631840635838" CI_START="0.45708642506954733" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.334379721887974" LOG_CI_START="-0.3400016765556308" LOG_EFFECT_SIZE="-0.002810977333828425" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.9869638128731713" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.01633916459848162">
<NAME>Admission to neonatal intensive care unit</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.159631840635838" CI_START="0.4570864250695473" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.334379721887974" LOG_CI_START="-0.34000167655563085" LOG_EFFECT_SIZE="-0.002810977333828425" ORDER="11777" O_E="0.0" SE="0.39613497168753425" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.15692291579388357" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Women's assessment of their treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="104.10692657297561" CI_START="-26.10692657297561" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="39.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2008-04-24 16:09:50 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.24037619915013686" Q="0.0" RANDOM="NO" SCALE="125.89803968025078" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="49" UNITS="" WEIGHT="100.0" Z="1.174047054907212">
<NAME>Cost of treament (first 24 hours, in US$)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="104.10692657297561" CI_START="-26.10692657297561" EFFECT_SIZE="39.0" ESTIMABLE="YES" MEAN_1="246.0" MEAN_2="207.0" ORDER="11778" SD_1="172.0" SD_2="165.0" SE="33.218430076537494" STUDY_ID="STD-Guinn-1997" TOTAL_1="54" TOTAL_2="49" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7017864129960194" CI_START="0.3068086481208308" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="0.23090505194245328" LOG_CI_START="-0.513132402942673" LOG_EFFECT_SIZE="-0.1411136755001099" METHOD="MH" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.45720863943079637" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.0" Z="0.7434510719597822">
<NAME>Use of tocolytic drugs (not prespecified)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7017864129960194" CI_START="0.30680864812083075" EFFECT_SIZE="0.7225806451612903" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.23090505194245328" LOG_CI_START="-0.513132402942673" LOG_EFFECT_SIZE="-0.1411136755001099" ORDER="11779" O_E="0.0" SE="0.4370512840443243" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" VAR="0.19101382488479263" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.010467093305326" CI_START="-13.61046709330532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.15" MODIFIED="2008-04-24 16:09:56 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.36535886492642966" Q="0.0" RANDOM="NO" SCALE="19.05729816815738" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="56" UNITS="" WEIGHT="100.00000000000001" Z="0.9052011085010178">
<NAME>Time to delivery (days, not prespecified)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.010467093305326" CI_START="-13.61046709330532" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="55.7" MEAN_2="60.0" ORDER="11780" SD_1="26.9" SD_2="24.7" SE="4.7503256012585435" STUDY_ID="STD-Guinn-1997" TOTAL_1="62" TOTAL_2="56" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-10-15 15:34:49 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-10-15 15:34:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-08-16 08:41:16 +0100" MODIFIED_BY="[Empty name]">Methods used in previous versions of the review</TITLE>
<APPENDIX_BODY MODIFIED="2013-10-15 15:34:49 +0100" MODIFIED_BY="[Empty name]">
<P>The identified reports were read independently by two review authors to determine if the study met the inclusion criteria and to evaluate the methodological quality. Any disagreement was resolved by consensus.</P>
<P>Methodological quality of included trials was assessed using the methods described in the <I>Cochrane Handbook</I> (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>): Grade A: adequate concealment, Grade B: uncertain, Grade C: inadequate concealment. Other quality factors taken into consideration included blinding and losses to follow-up. Data were extracted independently by two of the review authors. The results were expressed as risk ratios for dichotomous outcomes and mean difference for continuous outcomes. Their 95% confidence intervals were computed, using the Cochrane Review Manager software (<LINK REF="REF-RevMan-2000" TYPE="REFERENCE">RevMan 2000</LINK>). In the case of significant heterogeneity between studies, a sensitivity analysis would have been performed to assess the impact on the results of study quality and characteristics. The following comparisons were performed: any type of hydration versus bed rest alone. Subgroup analysis would have included oral versus intravenous hydration and prelabour preterm rupture of membranes versus intact membranes, but separate data were not available. A subgroup analysis of women included at less than 34 weeks of gestation was performed.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>